pharmaphorum March 28, 2024
Sometimes the conversation about drug pricing within the pharma industry and the one going on in the wider world seem like they’re in completely different languages. But, as pharma learned in a big way last year, the political conversation around drug pricing can have a very real effect on their bottom lines and ways of doing business.
Everyone says they want more affordable drugs for patients that need them, but people disagree quite a bit on who’s to blame for the current status quo of sky-high prescription prices – not to mention how they might be corrected.
To help unpack some of those trends and conflicting perspectives, Brandon Newman, CEO of healthcare analytics firm Xevant, joins host Jonah Comstock on...
Today's Sponsors
Today's Sponsor